Can the effect of antiangiogenic treatments be monitored and quantified noninvasively by using contrast-enhanced US?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 20093504.
- Also identified by DOI 10.1148/radiol.091853.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Guibal et al (1) have demonstrated that contrast-enhanced US-derived parameters provide a noninvasive measure of tumor angiogenesis and, in particular, of the revascularization occurring after discontinuation of an antivascular endothelial growth factor (anti-VEGF) therapy. If these results can be reproduced in future clinical trials, contrast-enhanced US will enable the accurate monitoring of patient response to antiangiogenic therapies (including treatment suspensions), which should improve clinical outcomes.
Medical subject headings
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Contrast Media
- Neoplasms
- Neovascularization, Pathologic
- Vascular Endothelial Growth Factor A